Ligand Pharmaceuticals
LGND
286.85
-0.09
-0.03%
Ligand Pharmaceuticals
US · LGND
#1920 by market cap
Listed 1970
286.85
-0.09
-0.03%
Periodic snapshot; not a real-time feed.
· 2026-11-20 19:30
Recent news
-
Rating change
RBC Capital Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating, Raises Target Price to $345Market Newswire · 2026/8/7
-
Rating change
A Quick Look at Today's Ratings for Ligand Pharmaceuticals(LGND.US), With a Forecast Between $345 to $358Market Newswire · 2026/10/30
-
Rating change
RBC Capital Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating, Maintains Target Price $345Market Newswire · 2026/8/10
-
Rating change
BofA Securities Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating, Maintains Target Price $388Market Newswire · 2026/7/22
-
Rating change
A Quick Look at Today's Ratings for Ligand Pharmaceuticals(LGND.US), With a Forecast Between $388 to $397Market Newswire · 2026/9/23
-
Rating change
BofA Securities Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating, Raises Target Price to $406Market Newswire · 2026/10/19
-
H.C. Wainwright Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating, Maintains Target Price $358Market Newswire · 2026/11/12
-
Rating change
Citi Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating, Maintains Target Price $397Market Newswire · 2026/9/24
-
Rating change
A Quick Look at Today's Ratings for Ligand Pharmaceuticals(LGND.US), With a Forecast Between $326 to $370Market Newswire · 2026/8/8
-
Rating change
Oppenheimer Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating, Raises Target Price to $326Market Newswire · 2026/8/3
-
Barclays Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating, Raises Target Price to $350Market Newswire · 2026/11/11
-
RBC Capital Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating, Maintains Target Price $357Market Newswire · 2026/11/2
-
Rating change
Barclays Initiates Ligand Pharmaceuticals(LGND.US) With Buy Rating, Announces Target Price $345Market Newswire · 2026/9/25
-
A Quick Look at Today's Ratings for Ligand Pharmaceuticals(LGND.US), With a Forecast Between $345 to $406Market Newswire · 2026/10/31
-
Rating change
Citi Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating, Raises Target Price to $387Market Newswire · 2026/7/22
-
Citi Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating, Raises Target Price to $402Market Newswire · 2026/11/5
-
Rating change
Craig-Hallum Maintains Ligand Pharmaceuticals(LGND.US) With Buy RatingMarket Newswire · 2026/9/24
-
Rating change
H.C. Wainwright Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating, Raises Target Price to $358Market Newswire · 2026/8/7
-
Rating change
Stifel Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating, Maintains Target Price $332Market Newswire · 2026/8/14
-
Rating change
Citi Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating, Raises Target Price to $390Market Newswire · 2026/8/12
-
GUIDANCE: (LGND) Ligand Pharmaceuticals Expects 2026 Revenue Range $270M - $310M, Vs. FactSet Est of $289.5MMT Newswires · 2026/10/29
-
Rating change
Benchmark Co. Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating, Raises Target Price to $335Market Newswire · 2026/7/16
-
Rating change
H.C. Wainwright Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating, Maintains Target Price $358Market Newswire · 2026/9/24
-
Rating change
RBC Capital Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating, Raises Target Price to $340Market Newswire · 2026/7/15
-
Rating change
BofA Securities Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating, Raises Target Price to $388Market Newswire · 2026/7/9
Headlines are aggregated automatically and are not independently verified or edited by our team.
Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.
Ligand Pharmaceuticals discussion 0 comments